ABA Chemicals

What ABA Chemicals does

ABA Chemicals (雅本化学), founded in 2003 and listed on the Shenzhen ChiNext board in 2011 under ticker 300261, is a China-based contract development and manufacturing organization (CDMO/CRAMS) serving the global pharmaceutical and agrochemical industries. Its offering spans three product pillars: crop protection (formulations, active ingredients, and intermediates), pharmaceutical intermediates and APIs, and nutritional health products under the 'Wholly You' branded DTC line sold on Tmall, JD, Pinduoduo, and Xiaohongshu. The technology platform combines chiral synthesis, heterocyclic chemistry, sugar chemistry, biocatalysis (including engineered enzymes), and continuous-flow reactors (Corning AFR microreactors), supported by four R&D centers with over 10,000 square meters of lab space, a Fudan University joint laboratory, and a CAS academician workstation; the IP base is 132 domestic patents (66 invention patents) plus 7 international patents.

The operating footprint includes eight production bases across Malta, Taicang, Rudong, Binhai, Lanzhou, and Shangyu, with collaborative sites in Xiangyang and Fuxin, providing roughly 4,500 cubic meters of reactor capacity and multi-region supply optionality. Headcount sits in the 1,001-5,000 range, and the company has pursued inorganic capability additions including the acquisitions of Puyi Chemical and Yihui Biology (2016), Amino Chemicals Malta (2017), Anyang Erwang (2018), and A2W Pharma (2019).

The revenue model is B2B contract-based: long-cycle supply agreements with multinationals anchor volume (notably FMC, with a 3.5B yuan 2018-2021 contract renewed at 2B yuan for 2021-2024), complemented by an expanding list of Tier-1 customers including Bayer, Corteva, Roche, AbbVie, Novartis, Teva, Daiichi-Sankyo, Sumitomo, Hengrui Medicine, GSK, and AstraZeneca. Revenue mechanics blend process R&D fees, milestone payments, and commercial supply at cGMP-grade quality, with ESG positioning (SBTi-validated net-zero targets, MSCI ESG upgrade from BBB to AA in 2025) increasingly tied to multinational procurement eligibility. The Wholly You line adds a smaller B2C revenue stream via Chinese e-commerce platforms.

Name

ABA Chemicals

Legal name

雅本化学股份有限公司

Website

https://abachem.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ABA Chemicals is a China-based CDMO/CRAMS provider serving global pharmaceutical and agrochemical clients, with eight production bases, four R&D centers, and a customer roster that includes FMC, Bayer, Corteva, Roche, AbbVie, Novartis, and Hengrui.

Ownership category

akta.pro rank

Product category

Custom Chemical Manufacturing (CDMO/CRAMS)

NAICS

Chemical Manufacturing (325), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Other Chemical Product and Preparation Manufacturing (3259)

SIC

Industrial Organic Chemicals (2860), Medicinal Chemicals & Botanical Products (2833), Chemicals & Allied Products (2800)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Contract Warehousing, Blending & Distribution for Agrochemicals (bulk handling, IBC/drum management) (AFABAIAL)

Keywords

• Pharmaceutical intermediates
• Agrochemical intermediates
• Contract manufacturing services
• Active pharmaceutical ingredients
• Custom chemical synthesis

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. CDMO/CRAMS Services: The company provides Contract Research, Development and Manufacturing Organization (CDMO/CRAMS) services including synthesis route design, process and analysis method development and optimization, kilogram-scale production, pilot-scale production, registration and verification batch production, and large-scale commercial production for pharmaceutical intermediates, agrochemical intermediates, and nutritional health products. Revenue is generated through project-based contracts with pharmaceutical and agrochemical companies.
2. Plant Protection Products: The company develops and manufactures plant protection (pesticide) products including intermediates and active ingredients. These are sold to major agrochemical companies globally.
3. Nutritional Health Products: The company produces and sells nutritional health products including NMN (β-Nicotinamide Mononucleotide), AKG (Alpha-Ketoglutarate), and other supplements targeting specific demographic groups (elderly, women, children). Products are sold through e-commerce platforms under the Wholly You® (和颐有雅) brand.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

ABA Chemicals is a CDMO (Contract Development and Manufacturing Organization) that develops, produces, and sells pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and plant protection (agrochemical) intermediates and active ingredients for global pharmaceutical and agrochemical clients. The company also produces and sells nutritional health products including NMN and AKG under the Wholly You® brand through Chinese e-commerce platforms. Services span synthesis route design, process development, kilogram-scale to commercial-scale manufacturing, with cGMP-compliant production facilities.

Product overview

ABA Chemicals Corporation is a CDMO (Contract Development and Manufacturing Organization) and consumer health company with three core business segments: plant protection products (agrochemical intermediates), pharmaceutical intermediates and APIs, and nutritional health products. Its core offering is the CDMO service platform providing end-to-end custom R&D and manufacturing from gram to commercial scale for pharmaceutical and agrochemical clients. On the consumer side, it sells nutritional supplements (NMN, AKG) under the Wholly You® brand via e-commerce platforms. The company operates multiple production bases across China and Malta, with R&D centers in Shanghai (Zhangjiang, Songjiang), Huzhou, and Lanzhou. Subsidiaries include Shanghai Puyi Chemical (acquired 2016) and Huzhou Yihui Biotechnology (acquired 2016), which provide specialized synthetic chemistry and biocatalysis capabilities. Product categories include plant protection intermediates, pharmaceutical intermediates, APIs, and nutritional products, with key technology platforms in chiral synthesis, heterocyclic chemistry, and biocatalysis.

Differentiator

Problem solved

Functional benefit

Brands

• Wholly You (Wholly You® / 颐有雅): Health and nutrition brand offering products including NMN, AKG and other supplements targeting elderly, women, and children. Debuted at CIIE and sold via Tmall, JD, Pinduoduo, and Xiaohongshu platforms.
• 雅本 (ABA)
• Crams
• 朴颐化学 (Puyi Chemical)

Products and services

• CDMO Services (Customized R&D and Manufacturing) High-end customized research, development, and manufacturing services (CDMO) covering synthesis route design, process and analysis method development and optimization, kilogram-scale production, pilot-scale production, registration and verification batch production, and large-scale commercial production for pharmaceutical and agrochemical clients.
• Pharmaceutical Intermediates and APIs Pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for the global pharmaceutical industry, produced via custom development and manufacturing (CDMO). Focus areas include non-natural amino acids, chiral alcohols, chiral amines, anti-tumor drug intermediates, anti-CNS drug intermediates, and cerebrovascular drug intermediates.
• Plant Protection Products (Agrochemical Intermediates and AIs) Plant protection (agrochemical) intermediates and active ingredients developed and manufactured as a CDMO for innovative crop protection solutions. Products include Trifloxystrobin (with a patented synthesis process, CN 118125941 B) and other pesticide intermediates supplied to multinational agrochemical companies.
• Wholly You® (和颐有雅) Nutritional Health Products Consumer health brand offering nutritional supplements including NMN (β-Nicotinamide Mononucleotide) and AKG (Alpha-Ketoglutarate) targeting specific demographic groups such as the elderly, women, and children. Sold through Tmall, JD.com, Pinduoduo, and Xiaohongshu.
• A2W Pharma Ltd CBD Products (Malta) CBD/cannabis-based pharmaceutical products manufactured by A2W Pharma Ltd, a wholly-owned subsidiary in Malta, with GMP certification for the CBD production line. Targets European and global pharmaceutical CBD markets.

Quantifiable outcome

• Successfully developed and industrialized dozens of pharmaceutical intermediate products, particularly in non-natural amino acids, chiral alcohols, and chiral amines
• +2 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core, support and major.

• Jiangsu Pesticide Research InstitutecoreStrategic or Co-development Partner · 18 September 2025Strategic cooperation agreement signed September 18, 2025 at ABAChem's Shanghai headquarters for collaborative development in innovative pesticides and agrochemical technology.
• Hengrui Medicine (恒瑞医药)coreStrategic or Co-development Partner · 1 August 2025Strategic partnership signed August 1, 2025 at Hengrui Tower in Shanghai's Zhangjiang area. Both parties committed to jointly propel product innovation and quality enhancement, strengthen synergistic competitiveness across critical pharmaceutical supply chain segments.
• DuPontsupportTechnology or Integration · 1 January 2024DuPont DSS safety management system implementation. DuPont senior experts conduct safety reviews and training at ABAChem facilities, including the Lanzhou Division.
• Shanghai Jiao Tong UniversitysupportStrategic or Co-development Partner · 1 January 2024Collaboration with Professor Yuanhai Su's research team to achieve breakthrough in Trifloxystrobin synthesis using microreactor technology.
• Central South UniversitysupportStrategic or Co-development Partner · 1 January 2024ABA Chem subsidiary Shangyan New Energy partnered with Central South University and Xi'an Jiaotong University for joint research published in international journal.
• FMC CorporationcoreStrategic or Co-development Partner · 1 January 2018Major strategic partnership with FMC for CDMO services. In 2018, entered a 3-year project cooperation worth 3.5 billion yuan. Contract was renewed in 2021 for another 3 years worth 2 billion yuan.
• Amino Chemicals Limited (Malta)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2017Acquired Malta-based Amino Chemicals Limited in 2017 for European market presence and CBD product development through subsidiary A2W Pharma Ltd.
• Puyi Chemical (朴颐化学) and Yihui Biology (颐辉生物)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2016Acquired in 2016 to strengthen pharmaceutical R&D capabilities and enter synthetic biology market.
• Fudan UniversitymajorStrategic or Co-development Partner · 25 November 2015Established Fudan ABA Chemical Joint Laboratory and ABA Fudan Joint Innovation Center at Shanghai Zhangjiang innovation center. Partnership includes sponsorship of '近思讲坛' (Jinsi Lecture) at Fudan Chemistry Department.
• Chinese Academy of Sciences Shanghai Institute of Organic ChemistrymajorStrategic or Co-development Partner · 25 November 2015Jointly built enterprise academician workstation and chiral compound development platform for process development resource sharing, raw material procurement, and industrialization.
• Shanghai R&D Public Service PlatformsupportTechnology or Integration · 25 November 2015Joined Shanghai R&D public service platform in 2014. Provides testing services to over 50 companies including Fosun Pharmaceutical, Yangzijiang Pharmaceutical, Huahai Pharmaceutical with nearly 10,000 samples tested annually.
• Chinese Academy of Sciences Shanghai Institute of Life Sciences - Huzhou Industrial Biotechnology CentermajorStrategic or Co-development Partner · 1 January 2009Collaboration with Huzhou Yihui Biotechnology to develop over 1,000 biocatalytic enzymes covering 78 categories, forming an enzyme preparation library.

Scale indicators12 records

Recent moves16 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Global CDMO incumbent providing small-molecule API, biocatalysis and complex chemistry at commercial scale. Direct overlap on technology stack (biocatalysis, chiral synthesis) but materially larger and geographically diversified.
• Catalent: Global CDMO offering softgel, oral dose and small-molecule API services to multinational pharma. Overlaps with ABA's CDMO/pharma intermediates offering but with broader formulation-led service mix.
• Pharmaron: Larger Chinese CRO/CDMO offering integrated drug discovery, preclinical and CMC manufacturing. Comparable customer profile but with a broader discovery-led service portfolio than ABA's CDMO-centric model.
• Siegfried Holding: Swiss CDMO offering API and intermediate manufacturing for branded and generic pharma. Comparable technology positioning in small-molecule custom synthesis, with a Western multinational customer base similar in profile to ABA's.

Direct peers

• Lianhetech: Chinese agrochemical and pharmaceutical intermediate CDMO serving multinational agro customers (including FMC-adjacent accounts). Closely comparable business mix, custom-manufacturing orientation, and pesticide-industry exposure.
• Zhejiang Huahai Pharmaceutical: Chinese API manufacturer with regulated-market focus (US FDA-inspected) and significant CDMO exposure. Comparable on cGMP API manufacturing and international pharma customer base, though larger commercial-API footprint.
• WuXi STA Pharmaceutical (WuXi AppTec subsidiary): Operates as WuXi AppTec's small-molecule CDMO arm, providing API and intermediate manufacturing from development to commercial scale — directly overlapping with ABA's core CDMO offering, including cGMP/FDA-inspected commercial manufacturing.
• Chongqing Huahai Pharmaceutical: Chinese API and intermediate manufacturer serving regulated generic and innovator pharma markets. Comparable in scale, regulatory positioning (cGMP) and reliance on Western multinational customers.
• Asymchem Laboratories: Chinese CDMO specializing in small-molecule APIs, intermediates and peptides with similar multinational pharma customer base. Closely comparable on service scope (CRO/CDMO integration), technology positioning, and customer profile (Western pharma + domestic).

Peers

• Novasep: European CDMO focused on complex small-molecule APIs and custom manufacturing. Comparable in size and service scope, with comparable technology depth in hazardous chemistry and chiral synthesis. Overlaps on agro and pharma custom manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aba-chemicals-corporation

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ABA Chemicals